IPAC meeting of October 2015

DECLARATION OF INTERESTS

All IPAC members participating in the meeting updated their declaration of interest ahead of the meeting. Other meeting participants, including observers, do not take part in the decision-making and are thus not required to complete a declaration of interest.

Six members reported relevant interests, all of which were assessed not to constitute a conflict of interest and these individuals will take part in full in all discussions. All the reported relevant interests are summarized below:

Robin Biellik
- Received consultancy fees from WHO/EURO to develop strategic plans and verification guidelines for measles elimination. The work was concluded in 2011. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from WHO/EMRO to develop verification guidelines for measles elimination. This work was concluded in 2012. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from WHO/HQ to support measles elimination activities. The work was concluded in 2013. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from ECDC to prepare report on pertussis. The work was concluded in 2013. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from UNICEF/Ethiopia to support measles elimination activities. The work was concluded in March 2014. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from PAHO to serve as a field team leader in two national EPI reviews in Mexico and Peru. The work was concluded in 2014. This interest was assessed as personal, non-specific and financially significant. *

Francois Gasse
- Receives consultancy fees from WHO to develop guidelines to sustain maternal and neonatal tetanus elimination. This work is on-going. This interest was assessed as personal, non-specific and financially significant. * Dr Gasse will recuse himself from decisions concerning the MNTE Session of the IPAC Meeting.
- Received consultancy fees form UNICEF for three consultations in Madagascar on immunization equity. This work is on-going. This interest was assessed as personal, non-specific and financially significant. *
- Receives consultancy fees from Becton Dickinson to provide technical advice on innovative technology concept for vaccine carriers and vaccine vials, to help review design/method for a field survey to test user acceptance and decision-maker acceptance, including the review of the survey results. This work was completed in 2013. This interest was assessed as personal, non-specific and financially significant. *
- Assisted KIWANIS in fundraising for MNTE. This interest was assessed as personal, non-specific and financially significant. *
Brad Gessner
- AMP receives project specific funding from Crucell, GSK, Hilleman Labs, Merck, Novartis, Pfizer, and Sanofi Pasteur. Recent work on delivery devices has included an assessment of acceptance and implementation issues for delivery of pentavalent vaccine in Uniject with funding from Crucell (ended 2014); assessment of a heat-stable rotavirus vaccine for Hilleman Labs (ended 2015); and evaluation of a measles aerosol delivery device with funding from WHO (ended 2012).
- AMP runs the LOGIVAC and LOGIVAC-Plus projects to implement a logistics training center in Benin and to develop innovative supply chain solutions with funding from BMGF.
- AMP provides technical support to five West African countries for all aspects of immunization implementation with funding from Gavi, the Vaccine Alliance.
- All funding is financially significant. During the past 10 years, he has not accepted personal reimbursement or fees (all funding goes to AMP).

Christopher Morgan
- Received consultancy fees from WHO/HQ over the period 2008-2011 to support work on hepatitis B birth dose. This included conducting a field trial in Papua New Guinea, writing a systematic literature review and organising a technical consultation. The work was concluded in 2011. This interest was assessed as non-personal, non-specific and financially significant. *
- Sat on the External Technical Advisory Board (ETAB) organized by Agence de Médicine Préventive to provide advice on the methodology, implementation and data analysis on optimal approaches of using Uniject to deliver DTP-HepB-Hib in Senegal and Vietnam; ended 2014. This study was funded by Crucell. This interest was assessed as non-personal, non-specific and financially insignificant.

Jean-Marc Olivé
- Receives consultancy fees from McKing, an institution financed by the Bill & Melinda Gates Foundation, to support polio eradication activities in priority African countries. The work is on-going and is primarily focused in Chad. This interest was assessed as personal, non-specific and financially significant. *

Robert Steinglass
- Sits on WHO’s Vaccine Product and Packaging Advisory Group (VPPAG). This interest was assessed as personal, non-specific and financially insignificant.
- Unrelated to agenda of this IPAC meeting, his institution is involved in many aspects of immunization with grants and contracts from BMGF, GAVI, UNICEF, USAID, and WHO.
- For cited activities, Mr Steinglass has never received lecture fees, honoraria nor research grants from industry.
- Sat on the External Technical Advisory Board (ETAB) organized by Agence de Médicine Préventive to provide advice on the methodology, implementation and data analysis on optimal approaches of using Uniject to deliver DTP-HepB-Hib in Senegal and Vietnam; ended 2014. This study was funded by Crucell. This interest was assessed as non-personal, non-specific and financially insignificant.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a "significant shareholding".